priors.science/reviews/anti-amyloid-antibodies

Anti Amyloid Antibodies

The current evidence on 12 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

12claims tracked

9 Aug 2026latest evidence review

Weeklyre-scored against new papers

4 Established · 2 Likely · 4 Uncertain · 2 Doubtful | four-reviewer panel · PICO Framework

ClaimStandingEvidence certaintyCorpus

Lecanemab and donanemab clear amyloidAmyloidEstablished90%35

Amyloid pathology required for benefitSelectionEstablished88%35

APOE4 homozygotes face higher amyloid-related imaging abnormality riskSafetyEstablished87%35

Donanemab slows decline in early Alzheimer's diseaseEfficacyLikely83%4

Lecanemab slows decline in early Alzheimer's diseaseEfficacyLikely80%4

Anti-amyloid drugs are disease-modifyingClinical MeaningfulnessUncertain67%4

Second-generation versus first-generation antibodies in Alzheimer's diseaseEfficacyUncertain59%35

Amyloid clearance and clinical outcomesAmyloidUncertain53%35

Low tau burden predicts better responseSelectionUncertain52%35

Aducanumab clinical benefit unprovenEfficacyDoubtful40%35

Anti-amyloid effects exceed minimal clinically important differenceClinical MeaningfulnessDoubtful38%35

Track Anti Amyloid Antibodies.

These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.

Track this topic →

Standing — what the evidence certainty means

Established≥ 85%Strong, consistent evidence. Unlikely to change.

Likely70–84%Well supported, with some gaps or indirect evidence.

Uncertain50–69%Mixed or limited evidence. Genuinely open.

Doubtful30–49%Little support; the weight of evidence leans against it.

Refuted< 30%The evidence contradicts it — confidently false as stated.